Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice

Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from routine clinical practice, especially in Asian patients. Global ETNA (Edoxaban in rouTine cliNical prActice) is a nonin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eue-Keun Choi, Wei-Shiang Lin, Gyo-Seung Hwang, Paulus Kirchhof, Raffaele De Caterina, Cathy Chen, Martin Unverdorben, Chun-Chieh Wang, Young-Hoon Kim
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	atrial fibrillation edoxaban real-world data Asia ETNA Medicine R
Acceso en línea:	https://doaj.org/article/572bb07d56b040df9518e3e34245b702
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:572bb07d56b040df9518e3e34245b702
record_format	dspace
spelling	oai:doaj.org-article:572bb07d56b040df9518e3e34245b7022021-11-25T18:01:52ZClinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice10.3390/jcm102253372077-0383https://doaj.org/article/572bb07d56b040df9518e3e34245b7022021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5337https://doaj.org/toc/2077-0383Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from routine clinical practice, especially in Asian patients. Global ETNA (Edoxaban in rouTine cliNical prActice) is a noninterventional study that integrates data from patients from multiple regional registries into one database. Here, we report the 1-year clinical events from AF patients receiving edoxaban in South Korea and Taiwan. Clinical events assessed included bleeding, strokes, systemic embolic events, transient ischemic attacks (TIAs), and all-cause and cardiovascular death. Overall, 2677 patients (mean (range) age 72 (66–78) years, male 59.7%, mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score ± standard deviation 3.1 ± 1.4) were treated with 60 or 30 mg edoxaban and had 1-year follow-up data. The annualized event rates for major bleeding and clinically relevant non-major (CRNM) bleeding were 0.78% and 0.47%, respectively. Annualized event rates for ischemic stroke and hemorrhagic stroke were 0.90% and 0.19%, respectively. Event rates for major and CRNM bleeding and rates of ischemic stroke and TIA were higher in Taiwanese patients than in Korean patients. Event rates were low and similar to those found in other studies of edoxaban in Korean and Taiwanese AF patients, thus supporting the safety and effectiveness of edoxaban in this population.Eue-Keun ChoiWei-Shiang LinGyo-Seung HwangPaulus KirchhofRaffaele De CaterinaCathy ChenMartin UnverdorbenChun-Chieh WangYoung-Hoon KimMDPI AGarticleatrial fibrillationedoxabanreal-world dataAsiaETNAMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5337, p 5337 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atrial fibrillation edoxaban real-world data Asia ETNA Medicine R
spellingShingle	atrial fibrillation edoxaban real-world data Asia ETNA Medicine R Eue-Keun Choi Wei-Shiang Lin Gyo-Seung Hwang Paulus Kirchhof Raffaele De Caterina Cathy Chen Martin Unverdorben Chun-Chieh Wang Young-Hoon Kim Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
description	Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from routine clinical practice, especially in Asian patients. Global ETNA (Edoxaban in rouTine cliNical prActice) is a noninterventional study that integrates data from patients from multiple regional registries into one database. Here, we report the 1-year clinical events from AF patients receiving edoxaban in South Korea and Taiwan. Clinical events assessed included bleeding, strokes, systemic embolic events, transient ischemic attacks (TIAs), and all-cause and cardiovascular death. Overall, 2677 patients (mean (range) age 72 (66–78) years, male 59.7%, mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score ± standard deviation 3.1 ± 1.4) were treated with 60 or 30 mg edoxaban and had 1-year follow-up data. The annualized event rates for major bleeding and clinically relevant non-major (CRNM) bleeding were 0.78% and 0.47%, respectively. Annualized event rates for ischemic stroke and hemorrhagic stroke were 0.90% and 0.19%, respectively. Event rates for major and CRNM bleeding and rates of ischemic stroke and TIA were higher in Taiwanese patients than in Korean patients. Event rates were low and similar to those found in other studies of edoxaban in Korean and Taiwanese AF patients, thus supporting the safety and effectiveness of edoxaban in this population.
format	article
author	Eue-Keun Choi Wei-Shiang Lin Gyo-Seung Hwang Paulus Kirchhof Raffaele De Caterina Cathy Chen Martin Unverdorben Chun-Chieh Wang Young-Hoon Kim
author_facet	Eue-Keun Choi Wei-Shiang Lin Gyo-Seung Hwang Paulus Kirchhof Raffaele De Caterina Cathy Chen Martin Unverdorben Chun-Chieh Wang Young-Hoon Kim
author_sort	Eue-Keun Choi
title	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
title_short	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
title_full	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
title_fullStr	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
title_full_unstemmed	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
title_sort	clinical events with edoxaban in south korean and taiwanese atrial fibrillation patients in routine clinical practice
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/572bb07d56b040df9518e3e34245b702
work_keys_str_mv	AT euekeunchoi clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice AT weishianglin clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice AT gyoseunghwang clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice AT pauluskirchhof clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice AT raffaeledecaterina clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice AT cathychen clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice AT martinunverdorben clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice AT chunchiehwang clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice AT younghoonkim clinicaleventswithedoxabaninsouthkoreanandtaiwaneseatrialfibrillationpatientsinroutineclinicalpractice
_version_	1718411680159891456

Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice

Ejemplares similares